BridgeMD
Compares treatment options for ST Elevation Myocardial Infarction
Official title OCT Versus Angiography for Culprit Lesion Revascularization in Acute Myocardial Infarction PatiEnts
ClinicalTrials.gov ID: NCT06227754
What this study is testing
- What it's testing
- The aim of the study is to compare clinical outcomes between optical coherence tomography-guided versus angiography-guided percutaneous coronary intervention (PCI) in patients with acute myocardial infarction (AMI).
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 19 and older
You may be able to join if
- Subject must be at least 19 years of age
- Acute ST-segment elevation myocardial infarction (STEMI) \ STEMI: ST-segment elevation ≥0.1 mV in ≥2 contiguous leads or documented newly developed...
- Primary percutaneous coronary intervention (PCI) in \< 12 h after the onset of symptoms for STEMI patients
- Subject is able to verbally confirm understandings of risks, benefits and treatment alternatives of receiving invasive physiologic evaluation and PCI...
You likely can't join if
- Target lesions not amenable for PCI by operators' decision
- Ostial lesions located in left main vessel or right coronary artery (left main body or distal bifurcation lesions can be enrolled by operator's...
- Creatinine clearance ≤30 ml/min/1.73 m2 and not on dialysis (chronic dialysis dependent patients are eligible for enrolment regardless of creatinine...
- Cardiogenic shock (Killip class IV) at presentation
- Intolerance to Aspirin, Clopidogrel, Prasugrel, Ticagrelor, Heparin, or Everolimus
- Known true anaphylaxis to contrast medium (not allergic reaction but anaphylactic shock)
See the full eligibility criteria
- Subject must be at least 19 years of age
- Acute ST-segment elevation myocardial infarction (STEMI) \ STEMI: ST-segment elevation ≥0.1 mV in ≥2 contiguous leads or documented newly developed left bundle-branch block1
- Primary percutaneous coronary intervention (PCI) in \< 12 h after the onset of symptoms for STEMI patients
- Subject is able to verbally confirm understandings of risks, benefits and treatment alternatives of receiving invasive physiologic evaluation and PCI and he/she or his/her legally authorized representative provides...
- Target lesions not amenable for PCI by operators' decision
- Ostial lesions located in left main vessel or right coronary artery (left main body or distal bifurcation lesions can be enrolled by operator's discretion)
- Creatinine clearance ≤30 ml/min/1.73 m2 and not on dialysis (chronic dialysis dependent patients are eligible for enrolment regardless of creatinine clearance)
- Cardiogenic shock (Killip class IV) at presentation
- Intolerance to Aspirin, Clopidogrel, Prasugrel, Ticagrelor, Heparin, or Everolimus
- Known true anaphylaxis to contrast medium (not allergic reaction but anaphylactic shock)
- Pregnancy or breast feeding
- Non-cardiac co-morbid conditions are present with life expectancy \<2 year or that may result in protocol non-compliance (per site investigator's medical judgment)
- Unwillingness or inability to comply with the procedures described in this protocol
The study team makes the final eligibility decision.
Where it's taking place
- Daegu, Daegu, South Korea
- Gwangju, Gwangju, South Korea
- Iksan, Iksan, South Korea
- Incheon, Incheon, South Korea
- Jeju City, Jeju-do, South Korea
- Jeonju, Jeonju, South Korea
- Jinju, Jinju, South Korea
- Seoul, Seoul, South Korea
- Suncheon, Suncheon, South Korea
- Uijeongbu-si, Uijeongbu, South Korea
- Ulsan, Ulsan, South Korea
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 19 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Daegu, Daegu, South Korea; Gwangju, Gwangju, South Korea; Iksan, Iksan, South Korea; Incheon, Incheon, South Korea; Jeju City, Jeju-do, South Korea; Jeonju, Jeonju, South Korea and 5 more location(s). Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.